$TNGX News

TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data

Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate

Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?

Tango Therapeutics Sinks 13% on Pancreatic Cancer Data It Says “Surpass Any Published PDAC Datasets”

Tango Therapeutics stock falls despite positive cancer trial data

Tango Therapeutics (TNGX) Stock Looks Fully Valued After A 252% Run

Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In?

Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026

William Blair Initiates Coverage On Tango Therapeutics with Outperform Rating

Tango Therapeutics To Present Updated Data From Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib Or Zoldonrasib In Patients With MTAPdel/RASmut Metastatic PDAC And NSCLC At ESMO Congress 2026

Tango Therapeutics (TNGX) At 3.7x P B As Pullback Tests Whether It Looks Pricey

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $68

Tango Therapeutics: Promising Early Data, But A Long Road Ahead

Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $35

Tango Therapeutics Files Prospectus For Up To $400M Common Stock Offering

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Tango Therapeutics Q2 EPS $(0.37) Misses $(0.32) Estimate

Tango Therapeutics Announces Executive Chair Transition